Genedrive (LSE:GDR) Moat Score: 0/10 (As of Jul. 07, 2026)


What is Genedrive Moat Score?

Genedrive has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Genedrive has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Genedrive might have No Moat - No discernible moat.

Genedrive  (LSE:GDR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Genedrive Moat Score Related Terms

Genedrive Business Description

Other Exchanges D6M:Germany
Address Grafton Street, The Incubator Building, Manchester, GBR, M13 9XX
Genedrive PLC is a holding company engaged in the molecular diagnostics business. It operates in one operating segment named Diagnostics which is engaged in the Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and use in patient stratification (genotyping), pathogen detection, and other indications. Geographically the majority of the revenue is derived from the United Kingdom and also has its presence in Europe, United States of America and Rest of the World.